FDA grants accelerated approval to enfortumab vedotin-ejfv for metasta
Oncology news burst
Related Articles
Richard Pazdur, MD, Honored With the 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine
The 2025 AACR Enduring Impact Award for Transformative Service to Cancer Science and Medicine will be presented to Richard Pazdur, MD, during the AACR Annual…
Cancer Control Month, 2025
By the President of the United States of AmericaA Proclamation During Cancer Control Month, we honor the unwavering strength and courage of every American
FDA approves nivolumab with ipilimumab for hepatocellular carcinoma
On April 11, 2025, the FDA approved nivolumab with ipilimumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
FDA approves nivolumab with ipilimumab for hepatocellular carcinoma
On April 11, 2025, the FDA approved nivolumab with ipilimumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
FDA approves nivolumab with ipilimumab for hepatocellular carcinoma
On April 11, 2025, the FDA approved nivolumab with ipilimumab for the first-line treatment of unresectable or metastatic hepatocellular carcinoma.
FDA approves nivolumab with ipilimumab for colorectal cancer
On April 8, 2025, the FDA approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with colorectal cancer. Attachments
FDA approves nivolumab with ipilimumab for colorectal cancer
On April 8, 2025, the FDA approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with colorectal cancer. Attachments
FDA approves nivolumab with ipilimumab for colorectal cancer
On April 8, 2025, the FDA approved nivolumab with ipilimumab for adult and pediatric patients 12 years of age and older with colorectal cancer. Attachments
FDA approves brentuximab vedotin with lenalidomide and rituximab
On February 11, 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and rituximab.
FDA approves brentuximab vedotin with lenalidomide and rituximab
On February 11, 2025, the FDA approved brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in combination with lenalidomide and rituximab.